These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30939771)

  • 21. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
    Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
    Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
    Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential anti-cholinesterase and β-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits.
    Bhakta HK; Park CH; Yokozawa T; Tanaka T; Jung HA; Choi JS
    Arch Pharm Res; 2017 Jul; 40(7):836-853. PubMed ID: 28589255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
    Masaki S; Kii I; Sumida Y; Kato-Sumida T; Ogawa Y; Ito N; Nakamura M; Sonamoto R; Kataoka N; Hosoya T; Hagiwara M
    Bioorg Med Chem; 2015 Aug; 23(15):4434-4441. PubMed ID: 26145823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease.
    Meena P; Nemaysh V; Khatri M; Manral A; Luthra PM; Tiwari M
    Bioorg Med Chem; 2015 Mar; 23(5):1135-48. PubMed ID: 25624107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of central selective acetylcholinesterase inhibitors by means of a "bio-oxidisable prodrug" strategy.
    Bohn P; Le Fur N; Hagues G; Costentin J; Torquet N; Papamicaël C; Marsais F; Levacher V
    Org Biomol Chem; 2009 Jun; 7(12):2612-8. PubMed ID: 19503937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
    Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
    Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
    Liu S; Shang R; Shi L; Zhou R; He J; Wan DC
    Chem Biol Drug Des; 2014 Aug; 84(2):169-74. PubMed ID: 24890706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
    Hong C; Luo W; Yao D; Su YB; Zhang X; Tian RG; Wang CJ
    Bioorg Med Chem; 2014 Jun; 22(12):3213-9. PubMed ID: 24794747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
    Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
    Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
    Ogawa Y; Nonaka Y; Goto T; Ohnishi E; Hiramatsu T; Kii I; Yoshida M; Ikura T; Onogi H; Shibuya H; Hosoya T; Ito N; Hagiwara M
    Nat Commun; 2010 Oct; 1():86. PubMed ID: 20981014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
    Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
    Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
    Ghobadian R; Nadri H; Moradi A; Bukhari SNA; Mahdavi M; Asadi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Sharifzadeh M; Amini M
    Bioorg Med Chem; 2018 Sep; 26(17):4952-4962. PubMed ID: 30190181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
    Lan JS; Ding Y; Liu Y; Kang P; Hou JW; Zhang XY; Xie SS; Zhang T
    Eur J Med Chem; 2017 Oct; 139():48-59. PubMed ID: 28797883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.